



## **ESC Declaration of Interest Report**

### **2021 ESC/EACTS Guidelines for the management of valvular heart disease**

The ESC reviews relationships with industry and encourages transparency and ethical integrity.

It is mandatory for all experts involved in Guidelines development to comply with the ESC Declaration and Management of Conflict of Interest Policy. Under this policy, they are required to submit yearly Declaration of Interest (DOI) forms during the writing and reviewing phases of the Guidelines.

All DOIs are assessed prior to work commencing, and the ESC may decide to exclude any expert from a Guidelines activity based on the exclusion criteria as defined in the *ESC Declaration and Management of Conflict of Interest Policy, Annex 3*, as approved in July 2020.

The current policy and its annexes are available on the ESC website at [www.escardio.org/DOI](http://www.escardio.org/DOI)

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Baldus Stephan	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Vital : anticoagulation pharmaceuticals</li> <li>- CVRx : heart failure therapy</li> <li>- Abbott : heart valve therapy</li> <li>- Edwards Lifesciences : heart valve therapy</li> <li>- JenaValve Technology : heart valve therapy</li> <li>- Daiichi Sankyo : pharmaceuticals</li> <li>- MSD SHARP &amp; DOHME GMBH : pharmaceuticals</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Bayer Vital : anticoagulation pharmaceuticals</li> <li>- JenaValve Technology : heart valve therapy</li> <li>- Cardica Research GmbH : heart valve therapy</li> <li>- Daiichi Sankyo : pharmaceuticals</li> <li>- Novartis : pharmaceuticals</li> <li>- Amgen Inc : pharmaceuticals</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- JenaValve Technology : aortic valve therapy</li> <li>- Symetis SA : heart valve therapy</li> <li>- Biotronik : heart valve therapy</li> <li>- Pfizer : pharmaceuticals</li> <li>- Edwards Lifesciences : research grant</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Baldus Stephan	<b>2019</b> <ul style="list-style-type: none"> <li>- Abbott : structural heart disease, mitral valve regurgitation</li> <li>- Valtech : structural heart diseases</li> </ul>
	<b>2020</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Vital : anticoagulation pharmaceuticals</li> <li>- CVRx : heart failure therapy</li> <li>- Abbott : heart valve therapy</li> <li>- Edwards Lifesciences : heart valve therapy</li> <li>- JenaValve Technology : heart valve therapy</li> <li>- Daiichi Sankyo : pharmaceuticals</li> <li>- MSD SHARP &amp; DOHME GMBH : pharmaceuticals</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Bayer Vital : anticoagulation pharmaceuticals</li> <li>- JenaValve Technology : heart valve therapy</li> <li>- Cardica Research GmbH : heart valve therapy</li> <li>- Daiichi Sankyo : pharmaceuticals</li> <li>- Novartis : pharmaceuticals</li> <li>- Amgen Inc : pharmaceuticals</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : aortic valve therapy</li> <li>- JenaValve Technology : aortic valve therapy</li> <li>- Symetis SA : heart valve therapy</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Baldus Stephan	<p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Biotronik : heart valve therapy</li> <li>- Pfizer : pharmaceuticals</li> <li>- Abbott : structural heart disease, mitral valve regurgitation</li> <li>- Valtech : structural heart diseases</li> </ul>
Bauersachs Johann	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abiomed : acute heart failure</li> <li>- Daiichi Sankyo : Afib</li> <li>- Pfizer : Afib, Amyloidosis</li> <li>- Boehringer-Ingelheim : Afib, Diabetes mellitus, Heart Failure</li> <li>- Bayer : Afib, heart failure</li> <li>- Bristol Myers Squibb : Afib, heart failure</li> <li>- Merck Sharp &amp; Dohme : CAD, Hypercholesterolemia, heart failure</li> <li>- Abbott : Heart Failure</li> <li>- Medtronic : Heart Failure</li> <li>- Novartis : Heart Failure</li> <li>- Servier : Heart Failure</li> <li>- CVRx : Heart Failure</li> <li>- Vifor International : heart failure, hyperkalemia</li> <li>- Astrazeneca : heart failure, hyperkalemia</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Zoll Medical : Arrhythmia</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Bauersachs Johann	<b>2019</b> <ul style="list-style-type: none"> <li>- Abiomed : cardiogenic shock</li> <li>- Vifor International : Heart failure</li> <li>- CVRx : Heart Failure</li> </ul>
	<b>2020</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : Afib, Amyloidosis</li> <li>- Daiichi Sankyo : Afib, CAD</li> <li>- Boehringer-Ingelheim : Afib, Diabetes mellitus, Heart Failure</li> <li>- Bayer : Afib, heart failure</li> <li>- Bristol Myers Squibb : Afib, heart failure</li> <li>- Amgen : CAD, Heart Failure</li> <li>- Novartis : Heart Failure</li> <li>- Servier : Heart Failure</li> <li>- CVRx : Heart Failure</li> <li>- Cardior : Heart Failure</li> <li>- Vifor International : heart failure, hyperkalemia</li> <li>- Astrazeneca : heart failure, hyperkalemia</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Zoll Medical : Arrhythmia</li> <li>- Abiomed : cardiogenic shock</li> <li>- Vifor International : Heart failure</li> <li>- CVRx : Heart Failure</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Beyersdorf Friedhelm	<b>2019</b> Financial Declaration  Receipt of royalties for intellectual property. - Köhler-Chemie : Cardioplegia, Myocardial Protection
	<b>2020</b> Financial Declaration - Köhler Company : Cardioplegia, Myocardial Protection  Other Positions of Influence  Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. - Healthcare - OTHER - Scientific Founder and Shareholder of a Start-Up Company from the University Hospital Freiburg, Resuscitec GmbH
Capodanno Davide	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : Antithrombotic therapy - Bayer : Antithrombotic therapy - Boehringer-Ingelheim : Antithrombotic therapy - Daiichi Sankyo : Antithrombotic therapy - Sanofi Aventis : Antithrombotic therapy - Abbott : PCI - Biosensors : PCI - Boston Scientific : PCI - Amgen : Pharmacology

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Capodanno Davide	<p><b>2019</b></p> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> <li>- Supplier - Minor shareholder of CERC, an European CRO provider</li> </ul>
	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antithrombotic therapy</li> <li>- Bayer : Antithrombotic therapy</li> <li>- Boehringer-Ingelheim : Antithrombotic therapy</li> <li>- Daiichi Sankyo : Antithrombotic therapy</li> <li>- Medtronic : Coronary stents</li> <li>- Biotronik : Coronary stents</li> <li>- Menarini : Drugs</li> <li>- Amgen : Pharmacology</li> </ul> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> <li>- Supplier - Minor shareholder of CERC (&lt;5,000 Euros/year), a European CRO provider.</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Conradi Lenard	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Structural heart disease</li> <li>- Edwards Lifesciences : Structural heart disease</li> <li>- Medtronic : Structural heart disease</li> <li>- Abbott Laboratories : Structural heart disease</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Structural heart disease</li> <li>- Edwards Lifesciences : Structural heart disease</li> <li>- Medtronic : Structural heart disease</li> <li>- Abbott Laboratories : Structural heart disease</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Center of excellence for cerebral protection device (Sentinel)</li> </ul>
	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : Structural heart disease</li> <li>- Boston Scientific : Structural heart disease</li> <li>- Edwards Lifesciences : Structural heart disease</li> <li>- Medtronic : Structural heart disease</li> </ul>



## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Conradi Lenard	<p><b>2020</b></p> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Abbott : Structural heart disease</li> <li>- Boston Scientific : Structural heart disease</li> <li>- Edwards Lifesciences : Structural heart disease</li> <li>- Medtronic : Structural heart disease</li> </ul>
De Bonis Michele	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : Mechanical Circulatory Support (Consultancy and Proctorship)</li> <li>- Medtronic : Valves (Teaching Honoraria)</li> </ul> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Valves (Mitral valve repair Courses)</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Medtronic : EACTS 2019 Annual Meeting</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- Italian Patent N. 102017000052909: Articulated prosthesis for a tricuspid or mitral valve and related catching device (International Publication Number WO 2018/211346A1)</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
De Bonis Michele	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : Mechanical Circulatory Support (Consultancy and Proctorship)</li> <li>- Medtronic : Valves (Teaching Honoraria)</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Speaker fee for webinar</li> </ul>
De Paulis Ruggero	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : I participate in one Advisory Board in december 2109 receiving travel expanses and 1000 euro fee</li> </ul> <p>Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Mitral valve ring</li> </ul> <hr/> <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Advisory board</li> <li>- Edwards Lifesciences : Consultancy, speaker fee, advisory board, investigator</li> <li>- Terumo Inc : Speaker fee</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
De Paulis Ruggero	<p><b>2020</b></p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Investigator for Indure trial, Ascend and Replicate trial</li> </ul> <p>Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Mitral ring</li> </ul>
Delgado Victoria	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- GE Healthcare : 3-dimensional imaging workshop (2000 euro)</li> <li>- Medtronic : aortic stenosis (payment speaker fee 900 euro)</li> <li>- Bayer : diabetes - steering committee (750 euro)</li> <li>- Abbott Vascular : Mitraclip (payment speaker fee 1200 euro)</li> <li>- Edwards Lifesciences : tricuspid valve (payment speaker fee 1200 euro)</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Aortic valve stenosis</li> <li>- Bayer : Heart failure</li> <li>- Bioventrix : heart failure</li> <li>- Abbott Vascular : Mitraclip</li> <li>- Edwards Lifesciences : Tricuspid valve</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Delgado Victoria	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : aortic stenosis (speaker fee in 2019 &lt;1000 euro)</li> <li>- MSD : diabetes - speaker fee (800 euro)</li> <li>- GE Healthcare : echocardiography (&lt;2000 euro)</li> <li>- Novartis : heart failure (speaker fee 800 euro)</li> <li>- Abbott Vascular : Mitral valve disease (&lt;2000 euro)</li> <li>- Edwards Lifesciences : valvular heart disease (&lt;2000 euro)</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- GE Healthcare : echocardiography</li> <li>- Edwards Lifesciences : tricuspid valve disease</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- Member of AHA, associate editor of Circulation and JASE</li> </ul>
Freemantle Nick	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- University Hospitals NHS Foundation Trust : NHS Provider</li> </ul> <p>Research funding (personal) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Allergan : Device</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Freemantle Nick	<b>2019</b> <ul style="list-style-type: none"> <li>- Novo-Nordisk : Diabetes</li> <li>- Sanofi Aventis : Diabetes, RA</li> <li>- Astra Zeneca : Oncology</li> <li>- Takeda Pharmaceuticals : Oncology</li> <li>- Ipsen : Oncology</li> <li>- PCT : Statistics</li> <li>- ALK : Statistics</li> </ul>
	<b>2020</b> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- University Hospitals NHS Foundation Trust : NHS Provider</li> </ul> <p>Research funding (personal) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Allergan : Device</li> <li>- Sanofi Aventis : Diabetes, RA,</li> <li>- Astra Zeneca : Oncology</li> <li>- Ipsen : Oncology</li> <li>- MSD : Oncology</li> <li>- Aimmune : Peanut Allergy</li> <li>- ALK : Statistics</li> </ul>
Gilard Martine	<b>2019</b> <p>Financial Declaration</p> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Medtronic : French meetings</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Gilard Martine	<b>2019</b> <ul style="list-style-type: none"> <li>- Bayer Healthcare : travel to ACC</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> <li>- board of the French Society of Cardiology</li> </ul>
	<b>2020</b> <ul style="list-style-type: none"> <li>Nothing to be declared</li> </ul>
Haugaa Kristina Hermann	<b>2019</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Cardiogenetics</li> </ul>
	<b>2020</b> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Novartis : speaker fees</li> </ul>
Jeppsson Anders	<b>2019</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulation</li> <li>- LFB : Haemostasis</li> <li>- Octapharma : Haemostasis</li> <li>- Aqilion : Life science</li> <li>- XVIVO : Perfusion</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Jeppsson Anders	<p><b>2020</b></p> <p>Financial Declaration</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulation</li> <li>- Portola Pharmaceuticals : Anticoagulation</li> <li>- Werfen : Haemostasis</li> </ul>
Juni Peter	<p><b>2019</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other legal body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Fresenius Nutrition : ECCO2R in COPD</li> <li>- Ava : Fertility App</li> <li>- Amgen Inc : PCSK9 inhibitors in Patients at Cardiovascular Risk</li> </ul> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> <li>- Director, Applied Health Research Centre, St. Michael's Hospital</li> </ul> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- Peter Jüni serves as unpaid member of the steering group of trials funded by Abbott Vascular, Astra Zeneca, Biotronik, Biosensors, St. Jude Medical, Terumo and The Medicines Company, has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and honoraria to the institution for participation in advisory boards and/or consulting from Amgen, Ava and Fresenius, but has not received personal payments by any pharmaceutical company or device manufacturer.</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Juni Peter	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Fresenius Nutrition : ECCO2R in COPD</li> <li>- Ava : Fertility App</li> <li>- Appili Therapeutics : Infectious Diseases</li> <li>- Amgen Inc : PCSK9 inhibitors in Patients at Cardiovascular Risk</li> </ul> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> <li>- Director, Applied Health Research Centre, St. Michael's Hospital Scientific Director, Ontario COVID-19 Science Advisory Table</li> </ul> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- Peter Jüni serves as unpaid member of the steering group of trials funded by Abbott Vascular, Astra Zeneca, Biotronik, Biosensors, St. Jude Medical, Terumo and The Medicines Company, has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and honoraria to the institution for participation in advisory boards and/or consulting from Amgen, Ava and Fresenius, but has not received personal payments by any pharmaceutical company or device manufacturer.</li> </ul>
Milojevic Milan	<p><b>2019</b></p> <p>Nothing to be declared</p> <hr/> <p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Sorin Group : Intraoperative Cell Salvage</li> </ul>



## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Pierard Luc	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Abbott : Pacing - Biotronik : Pacing - Boehringer-Ingelheim : Speaker fees  Travel and meeting support from healthcare industry, independent of the above activities. - Abbott : Transcatheter edge to edge mitral valve repair: travel
	<b>2020</b> Nothing to be declared
Praz Fabien	<b>2019</b> Nothing to be declared
	<b>2020</b> Financial Declaration  Travel and meeting support from healthcare industry, independent of the above activities. - Edwards Lifesciences : Valvular heart disease (less than 1000€) - Abbott Vascular : Valvular heart disease (less than 1000€) - Polares Medical : Valvular heart disease (less than 1000€)  Other Positions of Influence  Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Participation as a local principal investigator in studies funded by Edwards Lifesciences, Abbott Vascular, and Polares Medical without impact on own remuneration. Unpaid member of the steering committee of the BRIGHT study funded by Abbott Vascular.

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Prendergast Bernard David	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Edwards Lifesciences : Transcatheter Heart Valves  Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Edwards Lifesciences : Epidemiology of heart valve disease
	<b>2020</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Abbott : COVID 19 - Edwards Lifesciences : Transcatheter Heart Valves - Anteris : Transcatheter Heart Valves  Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Edwards Lifesciences : Epidemiology of heart valve disease
Sadaba Rafael	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Atricure : Surgical ablation atrial fibrillation
	<b>2020</b>  Nothing to be declared

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Tribouilloy Christophe	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Novartis : congestive heart failure - BMS : echocardiography - Edwards Lifesciences : Mitral regurgitation: indications for surgery
	<b>2020</b> Nothing to be declared
Vahanian Alec	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Cardiovalve : transcatheter mitral valve replacement
	<b>2020</b> Financial Declaration - Cardiovalve : mitral valve replacement
Wojakowski Wojciech	<b>2019</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : DAPT - Boston Scientific : LAA closure, TAVI - Abbott Vascular : Mitral, TAVI, Stents, OCT - Balton : stants, valvuloplasty catheters - Medtronic : stents, TAVI

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Wojakowski Wojciech	<b>2019</b> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : TAVI</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : ESC congress</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> <li>- Valve for Life initiative in Poland</li> </ul>
	<b>2020</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- MyoKardia Inc : HOCCM</li> <li>- Boehringer-Ingelheim : NOAC</li> <li>- Pfizer : NOAC</li> <li>- Abbott Vascular : OCT, RFR</li> <li>- Astra Zeneca : P2Y12 inhibitors, flosins</li> <li>- Biotronik : stents</li> <li>- Balton : stents/valvuloplasty balloons</li> <li>- Medtronic : TAVI, stents</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Abdelhamid Magdy	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory board fees</li> <li>- Astra Zeneca : speaker fees</li> <li>- Boehringer-Ingelheim : speaker fees</li> <li>- Novartis : speaker fees</li> </ul>
Achenbach Stephan	<p><b>2020</b></p> <p>Nothing to be declared</p>
Antova Emilija	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Lek : Arterial Hypertension</li> </ul>
Aouad Aicha	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : beta blockers and calcic inhibitors</li> <li>- Novartis : GLT1agonits</li> <li>- Pfizer : oral anti coagulants</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Asteggiano Riccardo	<b>2020</b> Financial Declaration  Receipt of royalties for intellectual property. - Springer Nature Switzerland AG, : IB323946 Royalties Earned Current Period Royalties Due 1: Cardiac Management of Oncology Patients Edition 1 266979
Bakhutashvili Zviad	<b>2020</b>  Nothing to be declared
Barili Fabio	<b>2020</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Abbott : Aortic valve
Beitnes Jan Otto	<b>2020</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Abbott : Tricuspid valve interventions (speaker fee, appx 600 EUR)
Benchabi Yasmina	<b>2020</b>  Nothing to be declared
Borger Michael A	<b>2020</b> Financial Declaration  Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Cryolife : aortic surgery - Abbott : heart valve therapy - Edwards Lifesciences : heart valve therapy

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Borger Michael A	<b>2020</b> - Medtronic : heart valve therapy
Bouleti Claire	<b>2020</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : Heart Failure - Novartis : Heart Failure  Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Pfizer : Cardiac Amyloidosis
Boutsikou Maria	<b>2020</b>  Nothing to be declared
Bsata Walid	<b>2020</b>  Nothing to be declared
Bulatovic Nebojsa	<b>2020</b>  Nothing to be declared
Carrel Thierry	<b>2020</b> Financial Declaration  Receipt of royalties for intellectual property. - Swiss Cardiotech : Myocardial protection  Other Positions of Influence  Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. - Swiss Heart Foundation

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Cassar Demarco Daniela	<b>2020</b> Nothing to be declared
Cherniuk Sergii	<b>2020</b> Nothing to be declared
Chilingaryan Aram	<b>2020</b> Nothing to be declared
Collet Jean-Philippe	<b>2020</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. <ul style="list-style-type: none"> <li>- Amgen : Lipids</li> <li>- Astra Zeneca : Post-PCI antiplatelet treatment</li> <li>- Bristol Myers Squibb : Post-TAVR antithrombotic treatment</li> </ul> Research funding from healthcare industry under your direct/personal responsibility (to department or institution). <ul style="list-style-type: none"> <li>- Boston Scientific : Post-TAVR antithrombotic treatment</li> <li>- Bristol Myers Squibb : Post-TAVR antithrombotic treatment</li> </ul>
Dahl Jordi	<b>2020</b> Nothing to be declared
Danielsen Ragnar	<b>2020</b> Nothing to be declared
Elezi Shpend	<b>2020</b> Nothing to be declared



## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Foldager Dan	<p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.  - Private member of the danish heart association ("Hjerteforeningen") for whom I work as a volunteer (mentoring patients, patient supporter at Herlev Hospital, speaker a.o.)</p>
Glaveckaite Sigita	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.  - Servier : arterial hypertension  - Bayer Healthcare : chronic coronary syndromes  - Berlin Menarini : chronic coronary syndromes, arterial hypertension</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.  - President of the Lithuanian Heart Association</p>
Golino Paolo	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.  - Abbott Vascular : Left Atrial Appendage Closure Proctorship</p>
Gonzalez Gomez Ariana	<p><b>2020</b></p> <p>Nothing to be declared</p>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Habib Gilbert	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : heart failure</li> <li>- Abbott : mitraclip</li> <li>- Actelion : pulmonary hypertension</li> </ul>
Hassager Christian	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abiomed : Speaker fees</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> <li>- President of the Danish Heart Foundation (a patient organisation)</li> </ul>
Irs Alar	<p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- I am also employed by the Estonian State Agency of Medicines, a governmental medicines regulatory agency. I am a member of the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA). I am a board member of the Estonian Society of Cardiology which receives funding from healthcare industry for its activities. I am not responsible for the organisations financial dealings nor any of its projects funded by the industry.</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Irtyuga Olga	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : arterial hypertension, chronic heart disease</li> <li>- Aspen Pharma : Coagulation</li> <li>- Pfizer : Coagulation, Atrial Fibrillation</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : Pulmonary hypertension</li> </ul>
Iung Bernard	<p><b>2020</b></p> <p>Nothing to be declared</p>
Ivanovic Branislava	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Speaker fee</li> <li>- Pfizer : Speaker fee</li> <li>- Berlin Chemie AG : Speaker fee</li> <li>- Merck Sharp &amp; Dohme : Speaker fee</li> <li>- PharmaSwiss : Speaker fee</li> <li>- Amicus : Speaker fee</li> <li>- Hemofarm : Speaker fee</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- ESC Congress - Hemofarm : Hypertension, Infective endocarditis</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Jahangiri Marjan	<b>2020</b>  Nothing to be declared
Karakiriou Maria	<b>2020</b>  Nothing to be declared
Katus Hugo	<b>2020</b>  Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Boehringer Ingelheim : Symposium General Cardiology  Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Bayer AG : Chair symposium anticoagulation therapies  Other Positions of Influence  Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease. - Healthcare - HEART FAILURE - Co-founder of a start up on gene therapy (AaviGen) for heart failure. No earnings
Kerimkulova Alina	<b>2020</b>  Nothing to be declared
Kertesz Attila	<b>2020</b>  Nothing to be declared
Khanji Mohammed Yunus	<b>2020</b>  Nothing to be declared
Korkmaz Levent	<b>2020</b>  Nothing to be declared

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Koskinas Konstantinos	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Cardiology</li> <li>- Daiichi Sankyo : Cardiology</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Cardiology</li> </ul>
Lancellotti Patrizio	<p><b>2020</b></p> <p>Nothing to be declared</p>
Massberg Steffen	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Antithrombotic therapy</li> <li>- Bristol Myers Squibb : Antithrombotic therapy</li> <li>- Medtronic : Post MI management</li> <li>- Boston Scientific : TAVI</li> </ul> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> <li>- Deutsche Herzstiftung, member</li> </ul>
Meshael Marwa Sayed	<p><b>2020</b></p> <p>Nothing to be declared</p>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Metzler Bernhard	<b>2020</b>  Nothing to be declared
Mueller Christian Eugen	<b>2020</b>  Financial Declaration  Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. <ul style="list-style-type: none"> <li>- Bayer : Anticoagulants</li> <li>- Daiichi Sankyo : Anticoagulants And Lipid lowering</li> <li>- Boehringer-Ingelheim : Antidiabetics</li> <li>- Astra Zeneca : Anti-Diabetics</li> <li>- Idorsia : Antiplatelet therapy</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Acon : Diagnostics</li> <li>- Osler : Diagnostics</li> <li>- Novartis : Heart Failure</li> <li>- Sanofi Aventis : Lipid lowering</li> <li>- Amgen : Lipid-lowering</li> </ul> Research funding from healthcare industry under your direct/personal responsibility (to department or institution). <ul style="list-style-type: none"> <li>- Novartis : Diagnostics</li> <li>- BRAHMS GmbH : Diagnostics</li> <li>- OrthoClinical Diagnostics : Diagnostics</li> <li>- Abbott Laboratories : Diagnostics</li> <li>- Roche Diagnostics : Diagnostics</li> <li>- Siemens : Diagnostics</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Mueller Christian Eugen	<b>2020</b> <ul style="list-style-type: none"> <li>- Sphingotec : Diagnostics</li> <li>- quidel : Diagnostics</li> <li>- Upstream Medical Technologies : Diagnostics, Myocardial ischemia, BASEL VIII</li> </ul>
Myers Patrick	<b>2020</b> <p>Nothing to be declared</p>
Neumann Franz Josef	<b>2020</b> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Ferrer Internacional : Anticoagulant therapy</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Anticoagulant therapy</li> <li>- Pfizer : Anticoagulation</li> <li>- GlaxoSmithKline : Anticoagulation</li> <li>- Biotronik : Interventional Cardiology</li> <li>- Abbott Vascular : MitraClip, Xience Stent</li> <li>- Boston Scientific : Stents</li> <li>- Medtronic : Transcatheter Valves</li> </ul>
Nielsen Jens Cosedis	<b>2020</b> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> <li>- Member of Danish Heart Foundation</li> </ul> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- I received institutional research grants from the Novo Nordisk Foundation</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Ochala Andrzej	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Microport : investigator</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Microport : investigator</p>
Palecek Tomas	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Pfizer : amyloidosis - Alnylam : amyloidosis - Novartis : heart failure</p>
Palm Kairit	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Sanofi Aventis : Hypertrophic Cardiomyopathy</p>
Pedrizzini Giovanni B	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Abbott : Grant for MitraSwiss registry</p>



## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Pedrazzini Giovanni B	<p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. - Past president of the swiss society of cardiology</p>
Pibarot Philippe	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Edwards Lifesciences : Surgical and Transcatheter Valve Therapies - Medtronic : Surgical and Transcatheter Valve Therapies - Cardiac Phoenix : Surgical and Transcatheter Valve Therapies - Pi-Cardia : Surgical and Transcatheter Valve Therapies</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Edwards Lifesciences : Surgical and Transcatheter Valve Therapies - Medtronic : Surgical and Transcatheter Valve Therapies</p>
Rakisheva Amina	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Bayer : Atrial Fibrillation - Novartis : Heart Failure</p>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Ribeiras Regina	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Siemens Healthcare : ecocardiography</p> <p>Travel and meeting support from healthcare industry, independent of the above activities. - Genzyme : fabry disease</p>
Roffi Marco	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Biotronik : stents - Terumo Inc : Stents</p>
Rubboli Andrea	<p><b>2020</b></p> <p>Nothing to be declared</p>
Rudzitis Ainars	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Boehringer-Ingelheim : Atrial fibrillation/ Diabetes - Sanofi Aventis : Fabry disease - Takeda Pharmaceuticals : Fabry disease - Servier : Hypertension/Dyslipidemia - Bayer Healthcare : Oral anticoagulants</p>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Rudzitis Ainars	<b>2020</b> Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Sanofi Aventis : Fabry disease
Rustamova Yasmin	<b>2020</b> Nothing to be declared
Samardzic Jure	<b>2020</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Bayer : Anticoagulation - Servier : Coronary Artery Disease - Berlin Chemie AG : Coronary Artery Disease
Sarno Giovanna	<b>2020</b> Nothing to be declared
Sharipov Islamjan	<b>2020</b> Nothing to be declared
Shlyakhto Evgeny	<b>2020</b> Nothing to be declared
Shumavets Vadim	<b>2020</b> Nothing to be declared
Siepe Matthias	<b>2020</b> Nothing to be declared

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Simkova Iveta	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : pulmonary hypertension</li> <li>- AOP Orphan Pharmaceuticals : pulmonary hypertension</li> </ul>
Sitges Marta	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> <li>- Medtronic : Heart Valve Disease</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Atrial Fibrillation</li> <li>- Menarini : Continuous Education on Cardiovascular Diseases</li> <li>- Novartis : Heart Failure</li> <li>- Merck Sharp &amp; Dohme : Hypercholesterolemia</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Sitges Marta	<b>2020</b> Other Positions of Influence  Employment in healthcare industry (including part time) during the year for which you are declaring. - Speaker and consultant for Abbot.
Smajic Elnur	<b>2020</b> Nothing to be declared
Soendergaard Lars	<b>2020</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Abbott : TAVI - Boston Scientific : TAVI - Medtronic : TAVI
Sousa Uva Miguel	<b>2020</b> Nothing to be declared
Sow Rouguiatou	<b>2020</b> Financial Declaration  Travel and meeting support from healthcare industry, independent of the above activities. - Boehringer-Ingelheim : Inscription congrès Société Française de cardiologie
Tarantini Giuseppe	<b>2020</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Medtronic : stent and tavi - lecture fees - Boston Scientific : tavi - lecture fees

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Tarantini Giuseppe	<b>2020</b> - Edwards Lifesciences : tavi - lecture fees - Abbott Laboratories : tavi - lecture fees
Topilsky Yan	<b>2020</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Mitraltech : Tricuspid and Mitral Regurgitation - Edwards Lifesciences : Tricuspid Regurgitation  Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Edwards Lifesciences : Tricuspid Regurgitation
Trendafilova-Lazarova Diana	<b>2020</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Medtronic : Proctor
Tuleutayev Rustem	<b>2020</b> Financial Declaration  Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Medtronic : cardiac surgery, valvular heart diseases, atrial fibrillation surgery
van den Brink Renee Ba	<b>2020</b>  Nothing to be declared

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Vinereanu Dragos	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Acute Coronary Syndromes, Diabetes</li> <li>- Boehringer-Ingelheim : Atrial Fibrillation</li> <li>- Pfizer : Atrial Fibrillation</li> <li>- Novartis : Cardiovascular prevention, Heart Failure</li> <li>- Amgen : Heart failure</li> <li>- Servier : Hypertension, Heart Failure</li> </ul> <p>Research funding (personal) from healthcare industry.</p> <ul style="list-style-type: none"> <li>- Medpace : Clinical trial</li> <li>- PPD Global : Clinical trial</li> <li>- Dalcor : Clinical trial</li> <li>- Chiltern : Clinical trial</li> </ul>
Virtanen Marko	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Lecture fee</li> </ul>
Zakhama Lilia	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : cardiovascular risk</li> </ul>

## 2021 ESC/EACTS Guidelines for the management of valvular heart disease - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Zakhama Lilia	<p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Pfizer : dyslipemia</li> <li>- Novartis : heart failure</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : cardiovascular imaging</li> <li>- Merck Sharp &amp; Dohme : cardiovascular imaging</li> </ul>
Zamorano Gomez Jose Luis	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : anticoagulation</li> <li>- Pfizer : ANTICOagulation</li> <li>- Bayer AG : HEART FAILURE</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Abbott Laboratories : Valve</li> <li>- Edwards Lifesciences : Valve disease</li> </ul>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Abdelhamid Magdy	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory board fees</li> <li>- Astra Zeneca : speaker fees</li> <li>- Boehringer-Ingelheim : speaker fees</li> <li>- Novartis : speaker fees</li> </ul>
Aboyans Victor	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Antithrombotic therapies</li> <li>- Bristol Myers Squibb : Antithrombotic therapies</li> <li>- Astrazeneca : Diabetes</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Peripheral Artery Disease</li> </ul>
Antoniou Sotiris	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : speaker fees for education - AF</li> <li>- Bayer AG : speaker fees for education - AF</li> <li>- Daiichi Sankyo : speaker fees for education -AF</li> <li>- Astra Zeneca : speaker fees for education - CVD</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Antoniou Sotiris	<p><b>2020</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Astra Zeneca : Joint working initiative on improving CV care</p> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology. - Member of Arrhythmia alliance medical advisory panel</p>
Arbelo Elena	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Biosense Webster : Atrial fibrillation</p>
Asteggiano Riccardo	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Receipt of royalties for intellectual property. - Springer Nature Switzerland AG, : IB323946 Royalties Earned Current Period Royalties Due 1: Cardiac Management of Oncology Patients Edition 1 266979</p>
Baigent Colin	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution). - Boehringer-Ingelheim : Cardiovascular and renal disease</p>
Baumbach Andreas	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Astra Zeneca : Pharmacology</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Baumbach Andreas	<b>2020</b> <ul style="list-style-type: none"> <li>- CERC : Research Organisation: Events Committees</li> <li>- Abbot Vascular : Stents</li> <li>- Microport : Stents</li> <li>- Sinomed : Stents</li> <li>- Venus Medtech : Valves, CEP</li> </ul>
Borger Michael A	<b>2020</b> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Cryolife : aortic surgery</li> <li>- Abbott : heart valve therapy</li> <li>- Edwards Lifesciences : heart valve therapy</li> <li>- Medtronic : heart valve therapy</li> </ul>
Celutkienė Jelena	<b>2020</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : anticoagulation</li> <li>- Amgen : heart failure</li> <li>- Boehringer-Ingelheim : heart failure</li> <li>- Novartis : heart failure</li> <li>- Bayer Healthcare : heart failure</li> <li>- Astrazeneca : heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Roche Diagnostics : heart failure</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Cikes Maja	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Pfizer : Anticoagulation, amyloidosis</li> <li>- Astra Zeneca : coronary heart disease</li> <li>- Astra Zeneca : Heart Failure</li> <li>- Boehringer-Ingelheim : Heart failure</li> <li>- Novartis : Heart failure</li> <li>- Orion : Heart failure</li> <li>- Teva Pharmaceutical Industries : Heart failure</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : heart failure</li> <li>- CorVia : Heart failure</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Abbott : Heart failure</li> <li>- Novartis : Heart failure</li> </ul>
Collet Jean-Philippe	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Lipids</li> <li>- Astra Zeneca : Post-PCI antiplatelet treatment</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<p><b>2020</b></p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Post-TAVR antithrombotic treatment</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Post-TAVR antithrombotic treatment</li> <li>- Bristol Myers Squibb : Post-TAVR antithrombotic treatment</li> </ul>
Falk Volkmar	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Berlin Heart : Advisory</li> <li>- Novartis : Consultancy</li> <li>- Abbott : Educational Grant for HCP's</li> <li>- Edwards Lifesciences : Educational Grant for HCP's</li> <li>- Medtronic : Educational Grant for HCP's</li> <li>- Cryolife / Jotec : Educational Grant for HCP's</li> </ul>
Fauchier Laurent	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Healthcare</li> <li>- Boehringer-Ingelheim : Healthcare</li> <li>- Medtronic : Healthcare</li> <li>- Novartis : Healthcare</li> <li>- BMS/Pfizer : Healthcare</li> <li>- XO : Healthcare</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Gale Christopher Peter	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acs hf</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : af</li> <li>- Abbott : diabetes</li> </ul>
Halvorsen Sigrun	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Anticoagulation</li> <li>- Sanofi Aventis : Lipidlowering</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation</li> <li>- Pfizer : Anticoagulation</li> <li>- Novartis : Heart failure</li> </ul>
Iung Bernard	<p><b>2020</b></p> <p>Nothing to be declared</p>
Jaarsma Tiny	<p><b>2020</b></p> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Konradi Aleksandra	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : hypertension</li> <li>- Krka Pharma : hypertension</li> <li>- Gedeon Richter : hypertension</li> <li>- Servier : hypertension</li> </ul>
Koskinas Konstantinos	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : Cardiology</li> <li>- Daiichi Sankyo : Cardiology</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Cardiology</li> </ul>
Kotecha Dipak	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Data Science (Advisory Board)</li> <li>- Amomed : Data Science (Advisory Board)</li> <li>- Protherics Medicines Development : Data Science (Advisory Board)</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Kotecha Dipak	<p><b>2020</b></p> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Bayer : Funding for ESC STEEER-AF trial</li> <li>- Boston Scientific : Funding for ESC STEEER-AF trial</li> <li>- Daiichi Sankyo : Funding for ESC STEEER-AF trial</li> <li>- Boehringer Ingelheim : Funding for ESC STEEER-AF trial</li> <li>- BMS-Pfizer Alliance : Funding for ESC STEEER-AF trial</li> <li>- Amomed : Systematic review</li> </ul> <p>Other Positions of Influence</p> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- Grants from the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR HTA-130280 DaRe2THINK), the British Heart Foundation (PG/17/55/33087 and AA/18/2/34218), and the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074).</li> </ul>
Landmesser Ulf	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer AG : Advisory Board fee</li> <li>- Amgen : Speaker fee</li> <li>- Novartis : Speaker fee</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Novartis : Lipid Cardio Study</li> <li>- Bayer AG : Research Grant</li> </ul>



For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Lewis Basil S	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Vifor International : Heart failure</li> <li>- Kowa : Lipidology</li> <li>- CSL Behring : Lipidology, Secondary prevention</li> </ul> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Kowa : Lipidology</li> </ul>
Linhart Ales	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Arterial hypertension, coronary heart disease, heart failure</li> <li>- Boehringer-Ingelheim : Atrial fibrillation, diabetes</li> <li>- Sanofi Aventis : Fabry disease</li> <li>- Takeda Pharmaceuticals : Fabry disease</li> </ul>
Lochen Maja-Lisa	<p><b>2020</b></p> <p>Nothing to be declared</p>
Neubeck Lis	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Atrial fibrillation</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Neubeck Lis	<b>2020</b> <ul style="list-style-type: none"> <li>- Pfizer : Atrial fibrillation</li> <li>- Novo-Nordisk : CVD diabetes</li> <li>- Servier : Digital health</li> </ul>
Nielsen Jens Cosedis	<b>2020</b> <p>Other Positions of Influence</p> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> <li>- Member of Danish Heart Foundation</li> </ul> <p>Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> <li>- I received institutional research grants from the Novo Nordisk Foundation</li> </ul>
Petersen Steffen Erhard	<b>2020</b> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Circle Cardiovascular Imaging, Inc : Cardiac MRI and CT analysis and reporting software</li> </ul> <p>Other Positions of Influence</p> <p>Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: to reduce the burden of cardiovascular disease.</p> <ul style="list-style-type: none"> <li>- Healthcare - IMAGING - Circle Cardiovascular Imaging Inc., Calgary, Canada (25,000 shares at Canadian dollars \$1.50 each.)</li> </ul> <p>Membership or affiliation in political, advocacy or patients organisations working in the field of cardiology.</p> <ul style="list-style-type: none"> <li>- Membership British Cardiovascular Society, Royal College of Physicians, British Medical Association.</li> </ul>
Prescott Eva	<b>2020</b> <p>Nothing to be declared</p>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Rakisheva Amina	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Atrial Fibrillation</li> <li>- Novartis : Heart Failure</li> </ul>
Sitges Marta	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Direct personal payment from healthcare industry: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> <li>- Medtronic : Heart Valve Disease</li> </ul> <p>Travel and meeting support from healthcare industry, independent of the above activities.</p> <ul style="list-style-type: none"> <li>- Abbott : Heart Valve Disease</li> <li>- Edwards Lifesciences : Heart Valve Disease</li> </ul> <p>Research funding from healthcare industry under your direct/personal responsibility (to department or institution).</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Atrial Fibrillation</li> <li>- Menarini : Continuous Education on Cardiovascular Diseases</li> <li>- Novartis : Heart Failure</li> <li>- Merck Sharp &amp; Dohme : Hypercholesterolemia</li> </ul>

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2020.

Expert	Type of Relationship with Industry
Sitges Marta	<p><b>2020</b></p> <p>Other Positions of Influence</p> <p>Employment in healthcare industry (including part time) during the year for which you are declaring. - Speaker and consultant for Abbot.</p>
Touyz Rhian	<p><b>2020</b></p> <p>Financial Declaration</p> <p>Payment from healthcare industry to your department or institution or any other body for your personal services: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc. - Novartis : Consultancy-expert opinion</p>